SAB4500782
Anti-HER2 antibody produced in rabbit
affinity isolated antibody
Synonym(s):
C-erbB-2, Epidermal growth factor receptor-related protein, ErbB2, HER2, kinase ErbB2
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
biological source
rabbit
Quality Level
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
antigen 137 kDa
species reactivity
human, mouse, rat
concentration
~1 mg/mL
technique(s)
ELISA: 1:20000
immunofluorescence: 1:100-1:500
NCBI accession no.
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... ERBB2(2064)
Related Categories
General description
Human epidermal growth factor receptor 2 (HER2), or erb-b2 receptor tyrosine kinase 2 (ErbB2), is encoded by the gene mapped to human chromosome 17. The encoded protein belongs to the family of epidermal growth factors. HER2 membrane protein is characterized with a cysteine-rich extracellular ligand-binding domain, a hydrophobic membrane spanning region, and an intracellular tyrosine kinase domain. This protein does not have a ligand, and it either forms heterodimers with other family members or homodimer with itself when expressed at very high levels, to get activated. HER2 is expressed at low level in normal tissues, but at high level in breast cancer tissues.
Immunogen
The antiserum was produced against synthesized peptide derived from human HER2.
Immunogen Range: 661-710
Immunogen Range: 661-710
Biochem/physiol Actions
Human epidermal growth factor receptor 2 (HER2) signaling pathway stimulates cell proliferation and survival in the majority of breast cancers. Thus, overexpression of this protein causes breast cancer. Heterodimer complex of HER2 and phosphatidylinositide 3-kinase (PI3K) is the most potent stimulator of the PI3K/AKT anti-apoptosis pathway. Increased expression of HER2 is also observed in ovarian, colorectal, pancreatic, endometrial and gastric cancers. Trastuzumab, an antibody, works by binding to a domain in the external domain of HER2. This domain is missing in p95, a truncated form of HER2, and hence these cancer cells show resistance to trastuzumab. HER2 protein can be used as a prognostic marker and as a therapeutic option for gynecologic cancers.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
wgk_germany
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.
English DP, et al.
Molecular Diagnosis & Therapy, 17(2), 85-99 (2013)
The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology, 21(2), 382-389 (2016)
HER2: biology, detection, and clinical implications.
Gutierrez C and Schiff R.
Archives of Pathology & Laboratory Medicine, 135(1), 55-62 (2011)
Hayam A Aiad et al.
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 122(10), 976-984 (2014-03-19)
Breast carcinoma in Egyptian women is a biologically more aggressive disease than those diagnosed in Western women, although a substantial number of cases are hormone responsive. G protein-coupled receptor-30 (GPR30), a seven transmembrane domain protein, is currently recognized as an
Jing Lv et al.
Medical oncology (Northwood, London, England), 31(11), 280-280 (2014-10-10)
HER2 amplification and/or expression occurs in gastric carcinoma (GC), but the role of HER2 in the prognosis of GC remains unclear. The dysregulation of transforming acidic coiled coil 1 (TACC1), a downstream gene of HER2, is thought to be involved
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service